FPAS
INMB icon

Focus Partners Advisor Solutions’s INmune Bio INMB Stock Holding History

Focus Partners Advisor Solutions’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71K Buy
43,556
+531
+1% +$735 ﹤0.01% 1218
2026
Q1 		$48.6K Buy
43,025
+1,928
+5% +$2.75K ﹤0.01% 1219
2025
Q4 		$64.1K Buy
41,097
+147
+0.4% +$262 ﹤0.01% 1065
2025
Q3 		$84.8K Sell
40,950
-7,863
-16% -$18K ﹤0.01% 1100
2025
Q2 		$113K Buy
48,813
+37,224
+321% +$273K ﹤0.01% 1050
2025
Q1 		$90.5K Buy
+11,589
New +$92K ﹤0.01% 942

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Focus Partners Advisor Solutions's INMB Position: Q2 2026 in Review

Focus Partners Advisor Solutions increased its INmune Bio (INMB) stake by 1.2% in Q2 2026, buying an estimated $735 and bringing the position to 43,556 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #1218.

Focus Partners Advisor Solutions first reported a position in INMB in Q1 2025 and has held it in 6 quarters since. The position peaked at $113K in Q2 2025. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Focus Partners Advisor Solutions held 43,556 shares of INmune Bio worth $71K as of Q2 2026.
  • Focus Partners Advisor Solutions bought 531 INmune Bio shares in Q2 2026, an estimated $735.
  • INmune Bio made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #1218 holding.
  • Focus Partners Advisor Solutions first reported a position in INmune Bio in Q1 2025 and has held it in 6 quarters since.
  • Focus Partners Advisor Solutions's INmune Bio position peaked at $113K in Q2 2025.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.